{"id":123936,"date":"2026-09-01T19:40:16","date_gmt":"2026-09-01T19:40:16","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/123936\/"},"modified":"2026-09-01T19:40:16","modified_gmt":"2026-09-01T19:40:16","slug":"nurix-stock-up-29-in-a-month-heres-what-you-should-know","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/123936\/","title":{"rendered":"Nurix Stock Up 29% in a Month: Here&#8217;s What You Should Know |"},"content":{"rendered":"<p>Shares of Nurix Therapeutics\u00a0<a href=\"https:\/\/www.zacks.com\/stock\/quote\/NRIX\" rel=\"nofollow noopener\" target=\"_blank\">NRIX<\/a> have seen a sharp increase over the past month, primarily driven by growing investor optimism about the company\u2019s recently announced collaboration with Swiss pharma giant Roche\u00a0<a href=\"https:\/\/www.zacks.com\/stock\/quote\/RHHBY\" rel=\"nofollow noopener\" target=\"_blank\">RHHBY<\/a>.<\/p>\n<p>NRIX\u2019s Price Performance<\/p>\n<p>Shares of Nurix have rallied 28.6% in the past month compared with the <a href=\"https:\/\/www.zacks.com\/stocks\/industry-rank\/industry\/medical-biomedical-and-genetics-105\" rel=\"nofollow noopener\" target=\"_blank\">industry<\/a>\u2019s increase of 2.5%.<\/p>\n<p><img decoding=\"async\" alt=\"Zacks Investment Research\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/09\/168514.jpg\"\/><\/p>\n<p>Image Source: Zacks Investment Research<\/p>\n<p>Earlier this month, the companies signed an exclusive licensing and collaboration agreement to co-develop and co-commercialize one of Nurix\u2019s lead pipeline candidates, bexobrutideg (NX-5948), across various malignant hematology, immunology and neurology indications.<\/p>\n<p>Per the deal, Nurix is entitled to receive $700 million upfront and could earn up to $2.3 billion in total through development, regulatory, and commercial milestone payments from RHHBY. While Nurix will fund 40% of development costs, Roche will be covering the remaining 60%.<\/p>\n<p>However, the companies will equally share all profits and losses from net sales of the product upon potential approval and launch in the United States. In ex-U.S. markets, Roche will solely lead all commercialization activities, and Nurix will receive tiered royalties ranging from the low to high-teens<\/p>\n<p>The partnership is looking to build on Nurix\u2019s pioneering expertise in targeted protein degradation with Roche\u2019s leading portfolio of B-cell targeted therapies and clinical and commercial infrastructure.<\/p>\n<p>More on NRIX\u2019s Bexobrutideg Development<\/p>\n<p>Bexobrutideg is an investigational, orally bioavailable, brain-penetrant Bruton\u2019s tyrosine kinase (BTK) degrader being developed for the treatment of relapsed or refractory B-cell malignancies, as well as immunology and neurology indications. It uses a novel protein degradation mechanism that eliminates BTK rather than simply inhibiting it, potentially overcoming resistance associated with currently available BTK inhibitors.<\/p>\n<p>Bexobrutideg is expected to enter phase III testing in second-line chronic lymphocytic leukemia (CLL) later in 2026. Early clinical results suggest the therapy could deliver superior efficacy and tolerability compared with existing BTK inhibitors while potentially overcoming key resistance mechanisms.<\/p>\n<p>Beyond oncology, the clinical development plan for bexobrutideg also includes expanding into neurology and immunology, with phase II studies planned in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU).<\/p>\n<p>NRIX\u2019s Other Collaborations Deals<\/p>\n<p>Nurix is also progressing several partnered programs with large drugmakers like Sanofi <a href=\"https:\/\/www.zacks.com\/stock\/quote\/SNY\" rel=\"nofollow noopener\" target=\"_blank\">SNY<\/a>, Gilead\u00a0<a href=\"https:\/\/www.zacks.com\/stock\/quote\/GILD\" rel=\"nofollow noopener\" target=\"_blank\">GILD<\/a> and Pfizer.<\/p>\n<p>While Sanofi is advancing the STAT6 degrader, NX-3911, into clinical testing, Gilead is evaluating the IRAK4 degrader, GS-6791, in a phase I study. If these programs demonstrate encouraging clinical results, Nurix can choose to co-develop them and share U.S. profits. The company also expects to receive certain milestone payments from its collaborations with Gilead, Sanofi and Pfizer.<\/p>\n<p>        NRIX\u2019s Zacks Rank<\/p>\n<p>Nurix currently carries a Zacks Rank #3 (Hold). You can see\u00a0<a href=\"https:\/\/www.zacks.com\/stocks\/buy-list\/?ADID=zp_1link&amp;ICID=zpi%20_1link\" target=\"_blank\" rel=\"nofollow noopener\">the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here<\/a>.<\/p>\n<p>Beyond Nvidia: AI&#8217;s Second Wave Is Here<\/p>\n<p>The AI revolution has already minted millionaires. But the stocks everyone knows about aren&#8217;t likely to keep delivering the biggest profits. AI\u2019s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.<\/p>\n<p><a style=\"font-weight:bold\" href=\"https:\/\/www.zacks.com\/registration\/ultimatetrader\/welcome\/eoffer\/4e87?add=2205&amp;adid=SYND_BLOX_ZU_AIBOOMREPORTA_ANALYSTBLOG_284_06262026_2943803&amp;cid=CS-BLOX-FT-analyst_blog|price_surge_plunge-2943803\" rel=\"nofollow noopener\" target=\"_blank\">See Stocks Now &gt;&gt;<\/a><\/p>\n<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href=\"https:\/\/www.zacks.com\/registration\/pfp\/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BLOX_7BEST_ANALYSTBLOG_284_2943803&amp;cid=CS-BLOX-FT-analyst_blog|price_surge_\/_plunge-2943803\" target=\"_blank\" rel=\"nofollow noopener\">Click to get this free report<\/a><\/p>\n<p>\u00a0<\/p>\n<p><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=ZER_LINK&amp;t=NRIX&amp;ADID=SYND_BLOX_TCK_ANALYSTBLOG_284_2943803_NRIX&amp;cid=CS-BLOX-FT-analyst_blog|price_surge_\/_plunge-2943803\" rel=\"nofollow noopener\" target=\"_blank\">Nurix Therapeutics, Inc. (NRIX): Free Stock Analysis Report<\/a><\/p>\n<p>\u00a0<\/p>\n<p><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=ZER_LINK&amp;t=SNY&amp;ADID=SYND_BLOX_TCK_ANALYSTBLOG_284_2943803_SNY&amp;cid=CS-BLOX-FT-analyst_blog|price_surge_\/_plunge-2943803\" rel=\"nofollow noopener\" target=\"_blank\">Sanofi (SNY): Free Stock Analysis Report<\/a><\/p>\n<p>\u00a0<\/p>\n<p><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=ZER_LINK&amp;t=RHHBY&amp;ADID=SYND_BLOX_TCK_ANALYSTBLOG_284_2943803_RHHBY&amp;cid=CS-BLOX-FT-analyst_blog|price_surge_\/_plunge-2943803\" rel=\"nofollow noopener\" target=\"_blank\">Roche Holding AG (RHHBY): Free Stock Analysis Report<\/a><\/p>\n<p>\u00a0<\/p>\n<p><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=ZER_LINK&amp;t=GILD&amp;ADID=SYND_BLOX_TCK_ANALYSTBLOG_284_2943803_GILD&amp;cid=CS-BLOX-FT-analyst_blog|price_surge_\/_plunge-2943803\" rel=\"nofollow noopener\" target=\"_blank\">Gilead Sciences, Inc. (GILD): Free Stock Analysis Report<\/a><\/p>\n<p><a href=\"https:\/\/www.zacks.com\/stock\/news\/2943803\/nurix-stock-up-29-in-a-month-here-s-what-you-should-know?cid=CS-BLOX-FT-analyst_blog|price_surge_\/_plunge-2943803\" rel=\"nofollow noopener\" target=\"_blank\">This article originally published on Zacks Investment Research (zacks.com).<\/a><\/p>\n<p><a href=\"https:\/\/www.zacks.com\/\" rel=\"nofollow noopener\" target=\"_blank\">Zacks Investment Research<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Shares of Nurix Therapeutics\u00a0NRIX have seen a sharp increase over the past month, primarily driven by growing investor&hellip;\n","protected":false},"author":2,"featured_media":123937,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[58579,41223,41345,49080,41250,151,134,60640],"class_list":["post-123936","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-analyst-blog","tag-bexobrutideg","tag-bruton","tag-gild","tag-nrix","tag-rhhby","tag-roche","tag-sny"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117197486787720529","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/123936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=123936"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/123936\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/123937"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=123936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=123936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=123936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}